$VCEL

Wall Street Analysts Believe Vericel (VCEL) Could Rally 39.42%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 39.4% in Vericel (VCEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Original reporting
Zacks Commentary · Zacks Equity Research
Published Nov 10, 2025, 2:55 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 11, 2025, 1:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Wall Street Analysts Believe Vericel (VCEL) Could Rally 39.42%: Here's is How to Trade — source image
Decision brief

The 30-second read

$VCELBullishMed
01

Why it matters

If the projected upside materializes, VCEL could experience a rally, influencing biotech sector sentiment.

02

Market read

The news indicates a significant potential rally based on analyst sentiment, making it relevant for traders interested in biotech stocks.

03

What to watch

Potential regulatory hurdles, market volatility, or earnings miss could negate expected gains.

Timing: Short to medium term (1-3 months)

Background

Recent positive earnings estimate revisions and analyst price targets suggest increased investor optimism for VCEL.

Company-level read

Ticker impact

$VCELBullishMedium confidence
Context

High relevance due to positive analyst sentiment and significant upside potential.

Expected impact

Moderate to strong upward movement over the next 1-3 months.

Evidence & confidence

The consensus price target indicates upside, but the somewhat-bullish sentiment score and limited technical data suggest cautious optimism.

Market effects

Positive outlook for biotech and life sciences sectors, potentially lifting related stocks.

Limited regional impact, primarily US-focused due to company location.

Moderate, as biotech sector is globally interconnected but company-specific.

Counterpoint

The high upside projection may be overly optimistic; earnings revisions might not materialize, and technical indicators could signal overbought conditions.

Key entities

  • Vericel Corporation

    Biotech firm specializing in cell therapy products.

Related articles

$VCELMedAI 8/10

Vericel Q2 Earnings Call Highlights

Vericel (NASDAQ: VCEL) reported Q2 earnings call updates. Burn Care revenue rose 22% to about $12M, with Epicel at $10.4M and NexoBrid above $1.5M. 2026 guidance was raised to $330M-$340M total revenue, MACI to $284M-$290M, Burn Care to $46M-$50M, and Q3 revenue to $76.5M-$78.5M. Board authorized a $200M buyback.

$VCELHigh

Vericel Corp (VCEL): Results of Operations and Financial Condition

Vericel Corp (VCEL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991earningsreleaseq22026.htm EX-99.1 Document Exhibit 99.1 Vericel Corporation 25 Blue Sky Drive Burlington, MA 01803 T 617 588-5555 F 617 588-5554 www.vcel.com Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Sh

$LMTMedAI 8/10

What is Patriot missile system, why its supplies are down

The article explains the U.S.-made Patriot mobile air defense system and why interceptor missile supplies are down. It cites Raytheon and Lockheed for system details and notes CSIS estimates about 65% of U.S. interceptors were expended Feb to July, leaving under 850. It says the U.S. approved 5,250 interceptors for Gulf states and awarded Lockheed a contract up to $58.6B.

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.